On May 28, 2025, Brookfield Asset Management’s private equity arm and CDPQ have jointly acquired Antylia Scientific from GTCR in a transaction valued at approximately US$1.34 billion (C$1.83 billion at the time of the announcement). Headquartered in Vernon Hills, Illinois, Antylia is a diversified life sciences company serving the biopharmaceutical, clinical diagnostic, and environmental testing industries with critical laboratory products. The sale marks a major milestone in GTCR’s decade-long stewardship of Antylia, originally acquired in 2014 in a carve-out from Thermo Fisher Scientific under GTCR’s Leaders Strategy™. Over the years, GTCR partnered with Antylia Chairman Bernd Brust and CEO Jonathan Salkin to drive transformational growth through significant capital investments and 15 strategic add-on acquisitions. Notably, in 2021, Antylia divested its Masterflex bioprocessing segment to Avantor Inc. for US$2.9 billion, further refining its core focus areas. The transaction underscores Antylia's evolution into a key platform in life sciences tools and quality controls.

Simpson Thacher & Bartlett LLP advised Brookfield Asset Management’ in this transaction, while Mayer Brown advised CDPQ. Goldman Sachs and Jefferies served as financial advisors to Antylia, with Kirkland & Ellis providing legal counsel. J.P. Morgan Securities LLC advised GTCR.